Stockscreener 앱 받기
57.35
3.55%
-2.11
시간 외 거래:
57.35
Disc Medicine Inc 주식(IRON)의 최신 뉴스
Cantor Fitzgerald Predicts Disc Medicine FY2024 Earnings - MarketBeat
Disc Medicine Announces New Equity Sales Agreement - TipRanks
Wedbush Estimates Disc Medicine's Q4 Earnings (NASDAQ:IRON) - MarketBeat
Disc Medicine FY2024 EPS Estimate Boosted by Leerink Partnrs - MarketBeat
FY2024 EPS Estimate for Disc Medicine Increased by Analyst - MarketBeat
Disc Medicine FY2024 EPS Forecast Raised by HC Wainwright - MarketBeat
Paradigm Biocapital Advisors LP Adjusts Stake in Disc Medicine I - GuruFocus.com
Disc Medicine, Inc. (NASDAQ:IRON) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Wedbush Has Optimistic View of Disc Medicine FY2028 Earnings - MarketBeat
Disc Medicine Reports Q3 2024 Results and Strategic Progress - TipRanks
Disc Medicine (NASDAQ:IRON) Announces Quarterly Earnings Results - MarketBeat
Disc Medicine to Participate in Upcoming Investor Conferences - The Manila Times
Disc Medicine stock gets price target bump from H.C. Wainwright, Buy rating intact - Investing.com UK
Disc Medicine (IRON) to Present at Major Healthcare Investor Conferences | IRON Stock News - StockTitan
Learn to Evaluate (IRON) using the Charts - Stock Traders Daily
Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Disc Medicine Secures $200M Financing, Reports FDA Fast-Track Potential for Key Drug | IRON Stock News - StockTitan
Disc Medicine secures $200m financing to support trials - Clinical Trials Arena
Disc Medicine secures $200M in debt financing from Hercules Capital - MSN
Scotiabank Boosts Disc Medicine (NASDAQ:IRON) Price Target to $70.00 - Defense World
Wellington Management Group LLP Increases Stake in Disc Medicine Inc - GuruFocus.com
Disc Medicine Leaps on Investment - Baystreet.ca
Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital - citybiz
Disc Medicine Secures $200 Million in Financing - citybiz
Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc. - The Manila Times
Disc Medicine Secures Massive $200M Financing Deal to Advance Clinical Pipeline | IRON Stock News - StockTitan
FY2024 Earnings Forecast for Disc Medicine Issued By Wedbush - Defense World
Leerink Partnrs Forecasts Weaker Earnings for Disc Medicine - MarketBeat
Disc Medicine (NASDAQ:IRON) Stock Rating Upgraded by Raymond James - Defense World
FY2024 Earnings Estimate for Disc Medicine Issued By Wedbush - MarketBeat
Disc Medicine Announces Multiple Presentations Across - GlobeNewswire
Disc Medicine (IRON) Rally Strengthens With After-Hour Gains On Positive Clinical Milestone - Stocks Telegraph
Disc medicine director sells $427,525 in stock By Investing.com - Investing.com South Africa
Disc medicine director sells $427,525 in stock - Investing.com
Disc Medicine (NASDAQ:IRON) Stock Price Up 7%Here's Why - MarketBeat
HC Wainwright Reaffirms Buy Rating for Disc Medicine (NASDAQ:IRON) - MarketBeat
Scotiabank upgrades Disc Medicine shares target on trial update By Investing.com - Investing.com UK
Disc Medicine to Present Complete DISC-0974 Trial Data, Portfolio Updates at ASH 2024 | IRON Stock News - StockTitan
Disc Medicine stock target upgraded on bitopertin prospects By Investing.com - Investing.com Canada
Disc Medicine (NASDAQ:IRON) Upgraded at Morgan Stanley - MarketBeat
FDA aligns with Disc Medicine on EPP treatment study - Investing.com India
Wedbush Reaffirms Outperform Rating for Disc Medicine (NASDAQ:IRON) - MarketBeat
Disc over the moon as FDA urges Apollo bid with bitopertin in EPP - BioWorld Online
FDA aligns with Disc Medicine on EPP treatment study By Investing.com - Investing.com Canada
Disc Medicine stock rallies 26% on FDA update for bitopertin (update) - Seeking Alpha
Disc Medicine Shares Rise After Positive Feedback From FDA - Marketscreener.com
Disc Medicine (NASDAQ:IRON) Shares Gap UpTime to Buy? - MarketBeat
Disc Medicine leaps as it gets positive FDA feedback - The Pharma Letter
Raymond James increases Disc Medicine shares to Strong Buy on new drug - Investing.com UK
Disc Medicine (NASDAQ:IRON) Upgraded to Strong-Buy at Raymond James - MarketBeat
Disc Medicine Gains FDA Support for Bitopertin Trial - TipRanks
Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval - The Manila Times
Disc Medicine Announces Successful End of Phase 2 Meeting - GlobeNewswire
(IRON) Technical Data - Stock Traders Daily
Disc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP) - The Manila Times
Disc Medicine to Host Conference Call on End of Phase 2 FDA - GlobeNewswire
Disc Medicine, Inc. (NASDAQ:IRON) Short Interest Update - Defense World
3.66%
1.11%
자본화:
|
볼륨(24시간):